Építés alatt – nem éles oldal
Belépés
Befejeződött3. fázis

Multicenter Evaluation of Memory Remediation After TBI With Donepezil

A legfontosabb adatok

Ki végzi
Baylor College of Medicine
Hol
Charlestown, Elkins Park, Houston és Indianapolis (Egyesült Államok)Mind a 4 helyszín megnézése
Azonosító
Állapot
Befejeződött
Fázis
3. fázis
Résztvevők
75 fő vett részt
Kezdés
2013. szept. 1.
Befejezés
2024. dec. 4.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Donepezil
  • Placebo
A regiszteradat frissítve
2025. január 15.

Ki vehet részt

Életkor
18 év – 60 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 29 feltétel megnézéseKevesebb

Ki vehet részt

  • Man or woman of any race, color, ethnicity, or national origin
  • 18-60 years old
  • Primary language English
  • Clinical diagnosis of traumatic brain injury using National Institute of Neurological Disorders and Stroke TBI Common Data Elements definition and merit assignment of International Classification of Disease (ICD9) codes 850.0-850.9, 851.0, 851.2, 852.0, 852.2, 852.4, 853.0, or 854.0
  • TBI is non-penetrating
  • TBI is of complicated mild or greater severity
  • TBI occurred at least 6 months prior to study participation
  • Persistent posttraumatic memory impairment, as defined by HVLT-R Total Trials 1-3 (Form 3) impairment ≥ 25% for Wechsler Test of Adult Reading-based intelligence quotient-adjusted performance expectations
  • Memory impairments are functionally significant, as defined by subject and/or caregiver endorsement of at least 3 memory problems, occurring at least weekly, on the Everyday Memory Questionnaire
  • Stable doses of allowed centrally-acting medications for at least 3 months prior to study participation, and participant and caregiver commitment not to alter doses of allowed medications during study
  • Capable of providing independent informed consent for study participation or provision of consent for study participation by a legally-authorized representative is supported by subject assent to study participation
  • A knowledgeable informant is available and willing to attend study visits or to provide required information by telephone interview on the day of study visits

Ki nem vehet részt

  • Use of an excluded medication in the month prior to study participation, known allergy to donepezil, or documented intolerance to donepezil
  • Symptomatic bradycardia, cardiac conduction abnormality (i.e., first- or Type I second-degree atrioventricular blockade), atrial fibrillation, or unstable cardiovascular disease, including myocardial infarction within three months prior to study participation
  • Signs or symptoms of gastrointestinal bleeding or active peptic ulcer disease within three months prior to study participation
  • Pre-injury neurological and/or neurocognitive disorder
  • Primary diagnosis of hypoxic-ischemic brain injury or clinically definite post-TBI hypoxic-ischemic event (i.e., respiratory arrest and/or cardiac arrest) or non-TBI-related stroke
  • Pre- or post-injury psychotic and/or bipolar disorders
  • Post-injury substance use disorder (i.e., abuse or dependence diagnoses)
  • Posttraumatic epilepsy
  • Active, severe, or unstable pulmonary condition, including severe asthma
  • Clinically significant abnormalities on screening laboratory studies
  • Serum human chorionic gonadotropin (HCG)-confirmed pregnancy
  • Beck Depression Inventory-II (BDI-II) score ≥ 20 or BDI-II item 9 > 0
  • Brief Symptom Inventory 18 (BSI 18) Depression Subscale T score or Anxiety Subscale T score ≥ 63
  • Penetrating brain injury or cerebral lobectomy
  • Hearing, vision, and/or communication impairments that invalidate neuropsychological or other study assessments
  • Test of Memory Malingering Trial 2 score < 45
  • For female participants, unable/unwilling to use barrier contraception during study participation, intrauterine device, or other implantable contraceptive method, unable/unwilling to forego breastfeeding infants or children during study participation

Helyszínek itt: Egyesült Államok

  • Spaulding Rehabilitation HospitalCharlestown, Egyesült Államok
  • Moss Rehabilitation Research InstituteElkins Park, Egyesült Államok
  • TIRR Memorial HermannHouston, Egyesült Államok
  • Indiana UniversityIndianapolis, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a four-site, randomized, parallel design, double-blind, placebo-controlled, 10-week trial of donepezil 10 mg daily for verbal memory problems among adults with TBI in the subacute or chronic recovery period. The study will recruit 160 persons with TBI and functionally important memory problems during a four-year period of open recruitment.

A teljes eredeti leírásKevesebb

The study aims are:

1. To evaluate the effects of treatment with donepezil on verbal memory as assessed by the Hopkins Verbal Learning Test-Revised Total Trial 1-3; 2. To evaluate the effects of treatment with donepezil on memory-related activities as measured by the Everyday Memory Questionnaire; 3. To evaluate the effects of donepezil on attention, processing speed, neuropsychiatric symptoms, community participation, quality of life, and caregiver experiences.

A vizsgálat 2 csoportja

  • DonepezilMár használt kezelés, összehasonlításként

    Donepezil 5 mg capsules daily for 14 days. Donepezil 10 mg capsules daily for 56 days.

  • PlaceboPlacebo, összehasonlításként

    Placebo capsules once daily for 70 days.

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Four-site, Randomized, Parallel Design, Double-blind, Placebo-controlled, 10-week Trial of Donepezil 10 mg Daily for Verbal Memory Problems Among Adults With TBI in the Subacute or Chronic Recovery Period
A regiszteradat frissítve
2025. január 15.